| Literature DB >> 25165475 |
Kevin A Henry1, Recinda L Sherman2, Kaila McDonald3, Christopher J Johnson4, Ge Lin5, Antoinette M Stroup1, Francis P Boscoe6.
Abstract
Background. It remains unclear whether neighborhood poverty contributes to differences in subsite-specific colorectal cancer (CRC) incidence. We examined associations between census-tract poverty and CRC incidence and stage by anatomic subsite and race/ethnicity. Methods. CRC cases diagnosed between 2005 and 2009 from 15 states and Los Angeles County (N = 278,097) were assigned to 1 of 4 groups based on census-tract poverty. Age-adjusted and stage-specific CRC incidence rates (IRs) and incidence rate ratios (IRRs) were calculated. Analyses were stratified by subsite (proximal, distal, and rectum), sex, race/ethnicity, and poverty. Results. Compared to the lowest poverty areas, CRC IRs were significantly higher in the most impoverished areas for men (IRR = 1.14 95% CI 1.12-1.17) and women (IRR = 1.06 95% CI 1.05-1.08). Rate differences between high and low poverty were strongest for distal colon (male IRR = 1.24 95% CI 1.20-1.28; female IRR = 1.14 95% CI 1.10-1.18) and weakest for proximal colon. These rate differences were significant for non-Hispanic whites and blacks and for Asian/Pacific Islander men. Inverse associations between poverty and IRs of all CRC and proximal colon were found for Hispanics. Late-to-early stage CRC IRRs increased monotonically with increasing poverty for all race/ethnicity groups. Conclusion. There are differences in subsite-specific CRC incidence by poverty, but associations were moderated by race/ethnicity.Entities:
Year: 2014 PMID: 25165475 PMCID: PMC4137551 DOI: 10.1155/2014/823484
Source DB: PubMed Journal: J Cancer Epidemiol ISSN: 1687-8558
Overall CRC and subsite-specific age-adjusted incidence ratesa for men by poverty and race/ethnicity for selected areasb in the United States, 2005–2010.
| CT poverty | CRCc | Proximal colond | Distal colone | Rectumf | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| IR (95% CI) | IRR |
| IR (95% CI) | IRR |
| IR (95% CI) | IRR |
| IR (95% CI) | IRR | |
| All men | ||||||||||||
| <5% (low) | 29,704 | 49.6 (49–50.2) | Ref | 11,563 | 20.0 (19.6–20.4) | Ref | 7,117 | 11.7 (11.4–12.0) | Ref | 9,185 | 14.8 (14.4–15.1) | Ref |
| 5.0–9.9% | 34,495 | 49.9 (49.4–50.5) | 1.01 (0.99–1.02) | 13,338 | 19.8 (19.5–20.1) | 0.99 (0.97–1.01) | 8,523 | 12.2 (11.9–12.5) |
| 10,576 | 14.9 (14.6–15.2) | 1.01 (0.98–1.04) |
| 10.0–19.9% | 39,863 | 52.5 (51.9–50.0) |
| 14,933 | 20.1 (19.8–20.5) | 1.01 (0.98–1.03) | 10,052 | 13.1 (12.8–13.3) |
| 12,225 | 15.7 (15.4–16.0) |
|
| 20+ (high) | 26,224 | 56.6 (55.9–57.3) |
| 9,301 | 20.8 (20.4–21.2) |
| 6,813 | 14.5 (14.2–14.9) |
| 8,156 | 17.0 (16.6–17.4) |
|
| NHW men | ||||||||||||
| <5% (low) | 25,419 | 49.9 (49.3–50.5) | Ref | 10,083 | 20.3 (19.9–20.7) | Ref | 6,015 | 11.7 (11.4–12.0) | Ref | 7,752 | 14.8 (14.5–15.1) | Ref |
| 5.0–9.9% | 28,514 | 50.5 (49.9–51.1) | 1.01 (1.00–1.03) | 11,241 | 20.2 (19.8–20.5) | 0.99 (0.96–1.02) | 6,954 | 12.2 (11.9–12.5) |
| 8,615 | 15.1 (14.8–15.4) | 1.02 (0.99–1.05) |
| 10.0–19.9% | 29,532 | 53.5 (52.9–54.1) |
| 11,318 | 20.6 (20.2–21.0) | 1.01 (0.99–1.04) | 7,298 | 13.1 (12.8–13.4) |
| 8,973 | 16.2 (15.8–16.5) |
|
| 20+ (high) | 12,764 | 58.8 (57.8–59.8) |
| 4,632 | 21.5 (20.9–22.2) |
| 3,288 | 15.1 (14.5–15.6) |
| 3,937 | 18.0 (17.4–18.6) |
|
| NHB men | ||||||||||||
| <5% (low) | 1,262 | 57.3 (53.8–60.9) | Ref | 515 | 25.0 (22.6–27.5) | Ref | 312 | 14.1 (12.4–15.9) | Ref | 343 | 13.7 (12.1–15.4) | Ref |
| 5.0–9.9% | 2,143 | 54.2 (51.7–56.8) | 0.95 (0.88–1.02) | 883 | 23.1 (21.4–24.8) | 0.92 (0.82–1.05) | 511 | 12.8 (11.6–14.1) | 0.91 (0.78–1.06) | 610 | 14.4 (13.2–15.7) | 1.05 (0.91–1.22) |
| 10.0–19.9% | 4,199 | 57.9 (56.0–59.8) | 1.01 (0.94–1.08) | 1,693 | 24.5 (23.3–25.8) | 0.98 (0.88–1.10) | 1,007 | 13.7 (12.8–14.7) | 0.97 (0.85–1.12) | 1,166 | 14.6 (13.7–15.5) | 1.07 (0.93–1.22) |
| 20+ (high) | 6,955 | 68.3 (66.6–70.0) |
| 2,752 | 27.9 (26.8–29.0) |
| 1,730 | 16.8 (15.9–17.6) |
| 1,913 | 17.9 (17.0–18.7) |
|
| Hispanic men | ||||||||||||
| <5% (low) | 1,564 | 51.0 (48.2–53.8) | Ref | 549 | 19.4 (17.7–21.2) | Ref | 366 | 11.7 (10.4–13.1) | Ref | 529 | 15.7 (14.3–17.2) | Ref |
| 5.0–9.9% | 2,526 | 45.8 (43.9–47.8) |
| 864 | 16.6 (15.4–17.8) |
| 675 | 12.0 (11.1–13.1) | 1.03 (0.89–1.18) | 830 | 14.2 (13.2–15.2) | 0.90 (0.80–1.02) |
| 10.0–19.9% | 4,597 | 46.4 (45.0–47.9) |
| 1,510 | 16.4 (15.5–17.3) |
| 1,269 | 12.4 (11.7–13.2) | 1.06 (0.93–1.21) | 1,506 | 14.3 (13.5–15.1) | 0.91 (0.82–1.02) |
| 20+ (high) | 5,540 | 44.8 (44.8–46.1) |
| 1,673 | 14.4 (13.6–15.1) |
| 1,505 | 12.1 (11.4–12.7) | 1.03 (0.91–1.17) | 1,933 | 14.8 (14.1–15.6) | 0.94 (0.85–1.05) |
| API men | ||||||||||||
| <5% (low) | 1,459 | 39.5 (37.4–41.8) | Ref | 416 | 12.5 (11.3–13.8) | Ref | 424 | 11.4 (10.3–12.6) | Ref | 561 | 14.1 (12.9–15.3) | Ref |
| 5.0–9.9% | 1,312 | 40.2 (38.0–42.6) | 1.02 (0.94–1.10) | 350 | 11.5 (10.3–12.8) | 0.92 (0.79–1.07) | 383 | 11.8 (10.6–13.1) | 1.04 (0.89–1.20) | 521 | 15.1 (13.8–16.5) | 1.07 (0.95–1.22) |
| 10.0–19.9% | 1,535 | 43.7 (41.4–46.0) |
| 412 | 12.3 (11.1–13.6) | 0.98 (0.85–1.13) | 478 | 13.6 (12.4–14.9) |
| 580 | 15.9 (14.5–17.3) | 1.13 (1.00–1.28) |
| 20+ (high) | 965 | 45.1 (42.3–48.1) |
| 244 | 11.9 (10.4–13.5) | 0.95 (0.80–1.12) | 290 | 13.6 (12.1–15.3) |
| 373 | 16.9 (15.2–18.7) |
|
aRates are per 100,000 persons and age-adjusted to the 2000 US standard population.
bData are from selected population-based cancer registries that participate in the National Program of Cancer Registries (NPCR) and/or the Surveillance Epidemiology and End Results (SEER) Program: Arizona, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Iowa, Louisiana, Minnesota, New York, New Jersey, Texas, Utah, West Virginia, and Los Angeles.
cColon and rectum (CRC) included ICD-O-3 codes C18.0–C18.9, C19.9, C20.9, and C26.0.
dProximal included ICD-O-3 codes C18.0, C18.2, C18.3, C18.4, and C18.5.
eDistal included ICD-O-3 codes 18.6 and C18.7.
fRectum included ICD-O-3 codes C19.9 and C20.9.
IR: incidence rate; IRR: incidence rate ratio; CI: confidence interval; CT: census tract; NHW: non-Hispanic white; NHB: non-Hispanic black; API: Asian Pacific Islander.
Bold numbers indicate significant associations P < 0.05; reference (<5% below poverty).
Overall CRC and subsite-specific age-adjusted incidence ratesa for women by poverty and race/ethnicity for selected areasb in the United States, 2005–2010.
| CT poverty | CRCc | Proximal colond | Distal colone | Rectumf | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| IR (95% CI) | IRR |
| IR (95% CI) | IRR |
| IR (95% CI) | IRR |
| IR (95% CI) | IRR | |
| All women | ||||||||||||
| <5% (low) | 28,398 | 38.3 (37.8–38.8) | Ref | 13,086 | 17.6 (17.3–17.9) | Ref | 6,225 | 8.4 (8.2–8.7) | Ref | 6,969 | 9.4 (9.2–9.7) | Ref |
| 5.0–9.9% | 33,062 | 38.2 (37.8–38.6) | 1.00 (0.98–1.01) | 15,523 | 17.7 (17.4–18.0) | 1.00 (0.98–1.03) | 7,113 | 8.3 (8.1–8.5) | 0.98 (0.95–1.02) | 8,101 | 9.5 (9.3–9.7) | 1.01 (0.98–1.04) |
| 10.0–19.9% | 38,041 | 39.2 (38.8–39.6) |
| 17,586 | 17.8 (17.6–18.1) | 1.01 (0.99–1.04) | 8,622 | 9.0 (8.8–9.2) |
| 9,088 | 9.6 (9.4–9.8) | 1.01 (0.98–1.05) |
| 20+ (high) | 24,919 | 40.7 (40.2–41.2) |
| 10,994 | 17.8 (17.5–18.2) | 1.01 (0.99–1.04) | 5,823 | 9.6 (9.4–9.9) |
| 6,127 | 10.1 (9.9–10.4) |
|
| NHW women | ||||||||||||
| <5% (low) | 24,316 | 38.8 (38.3–39.3) | Ref | 11,432 | 18.0 (17.6–18.3) | Ref | 5,156 | 8.3 (8.1–8.6) | Ref | 5,891 | 9.6 (9.3–9.8) | Ref |
| 5.0–9.9% | 27,041 | 38.6 (38.1–39.1) | 1.00 (0.98–1.01) | 12,981 | 17.9 (17.6–18.3) | 1.00 (0.97–1.03) | 5,649 | 8.3 (8.1–8.5) | 0.99 (0.96–1.03) | 6,517 | 9.7 (9.5–9.9) | 1.01 (0.97–1.05) |
| 10.0–19.9% | 28,063 | 40.0 (39.5–40.5) |
| 13,441 | 18.4 (18.1–18.7) | 1.02 (1.00–1.05) | 6,101 | 9.0 (8.8–9.2) |
| 6,530 | 9.9 (9.6–10.1) | 1.03 (0.99–1.07) |
| 20+ (high) | 12,074 | 42.5 (41.7–43.3) |
| 5,582 | 18.6 (18.1–19.1) | 1.04 (1.00–1.07) | 2,652 | 9.8 (9.5–10.2) |
| 2,896 | 10.9 (10.5–11.3) |
|
| NHB women | ||||||||||||
| <5% (low) | 1,292 | 43.6 (41.2–46.1) | Ref | 605 | 21.1 (19.4–22.9) | Ref | 292 | 9.5 (8.4–10.7) | Ref | 308 | 10.0 (8.9–11.2) | |
| 5.0–9.9% | 2,385 | 43.9 (42.1–45.8) | 1.01 (0.94–1.08) | 1,118 | 21.2 (20.0–22.5) | 1.01 (0.91–1.11) | 524 | 9.3 (8.5–10.2) | 0.98 (0.85–1.14) | 562 | 9.9 (9.1–10.8) | 0.99 (0.86–1.15) |
| 10.0–19.9% | 4,625 | 45.3 (44.0–46.7) | 1.04 (0.98–1.11) | 2,099 | 21.0 (20.1–22.0) | 1.00 (0.91–1.09) | 1,099 | 10.6 (9.9–11.2) | 1.11 (0.97–1.28) | 1,051 | 10.0 (9.4–10.6) | 1.00 (0.88–1.14) |
| 20+ (high) | 7,342 | 48.7 (47.5–49.8) |
| 3,342 | 22.3 (21.6–23.1) | 1.06 (0.97–1.16) | 1,703 | 11.2 (10.7–11.7) |
| 1,707 | 11.1 (10.6–11.7) | 1.11 (0.98–1.27) |
| Hispanic women | ||||||||||||
| <5% (low) | 1,500 | 36.8 (34.9–38.7) | Ref | 607 | 16.2 (14.9–17.6) | Ref | 359 | 8.2 (7.3–9.1) | Ref | 411 | 9.2 (8.3–10.2) | Ref |
| 5.0–9.9% | 2,361 | 33.9 (32.5–35.3) |
| 991 | 15.0 (14.1–16.0) | 0.93 (0.83–1.03) | 567 | 7.8 (7.2–8.5) | 0.96 (0.83–1.10) | 612 | 8.3 (7.6–9.0) | 0.90 (0.79–1.02) |
| 10.0–19.9% | 3,979 | 31.9 (30.9–32.9) |
| 1,577 | 13.3 (12.6–14.0) |
| 1,003 | 7.7 (7.2–8.2) | 0.94 (0.83–1.07) | 1,088 | 8.4 (7.9–8.9) | 0.91 (0.81–1.03) |
| 20+ (high) | 4,611 | 30.8 (29.9–31.7) |
| 1,773 | 12.5 (11.9–13.1) |
| 1,209 | 7.7 (7.3–8.2) | 0.95 (0.84–1.07) | 1,245 | 8.0 (7.5–8.5) |
|
| API women | ||||||||||||
| <5% (low) | 1,290 | 28.6 (27.0–30.2) | Ref | 442 | 10.4 (9.4–11.4) | Ref | 418 | 8.9 (8.0–9.8) | Ref | 359 | 7.7 (6.9–8.6) | Ref |
| 5.0–9.9% | 1,275 | 30.1 (28.4 –31.8) | 1.05 (0.97–1.14) | 433 | 10.6 (9.6–11.7) | 1.02 (0.89–1.17) | 373 | 8.5 (7.7–9.4) | 0.96 (0.83–1.11) | 410 | 9.5 (8.6–10.5) |
|
| 10.0–19.9% | 1,374 | 30.6 (28.9–32.2) | 1.07 (0.99–1.16) | 469 | 11.0 (10.0–12.1) | 1.06 (0.92–1.21) | 419 | 9.1 (8.3–10.1) | 1.03 (0.89–1.18) | 419 | 8.9 (8.0–9.8) | 1.15 (0.99–1.33) |
| 20+ (high) | 892 | 32.1 (30.0–34.3) |
| 297 | 10.8 (9.6–12.1) | 1.04 (0.89–1.21) | 259 | 9.3 (8.2–10.5) | 1.04 (0.89–1.22) | 279 | 10.0 (8.8–11.2) |
|
aRates are per 100,000 persons and age-adjusted to the 2000 US standard population.
bData are from selected population-based cancer registries that participate in the National Program of Cancer Registries (NPCR) and/or the Surveillance Epidemiology and End Results (SEER) Program: Arizona, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Iowa, Louisiana, Minnesota, New York, New Jersey, Texas, Utah, West Virginia, and Los Angeles.
cColon and rectum (CRC) included ICD-O-3 codes C18.0–C18.9, C19.9, C20.9, and C26.0.
dProximal included ICD-O-3 codes C18.0, C18.2, C18.3, C18.4, and C18.5.
eDistal included ICD-O-3 codes 18.6 and C18.7.
fRectum included ICD-O-3 codes C19.9 and C20.9.
IRR: incidence rate ratio; CI: confidence interval; CT: census tract; NHW: non-Hispanic white; NHB: non-Hispanic black; API: Asian Pacific Islander.
Bold numbers indicate significant associations P < 0.05; reference (<5% below poverty).
CRC incidence rates for early and late stage tumors and late-to-early stage incidence rate ratios for men and women 50 years+ by race/ethnicity and poverty for selected areas in the United Statesa.
| CT poverty | CRCb early stagec | CRCb late staged | late-to-early stage | ||||
|---|---|---|---|---|---|---|---|
|
| Rate (95% CI) | IRR |
| Rate (95% CI) | IRR | ||
| All men | |||||||
| <5% (low) | 13,102 | 79.2 (77.8–80.6) | Ref | 13,419 | 81.1 (79.7–82.5) | Ref | 1.02 (1.00–1.05) |
| 5.0–9.9% | 14,969 | 78.2 (76.9–79.4) | 0.99 | 15,556 | 80.8 (79.5–82.1) | 1.00 | 1.03 (1.01–1.06) |
| 10.0–19.9% | 16,546 | 79.1 (77.9–80.3) | 1.00 | 18,497 | 87.6 (86.4–88.9) |
|
|
| 20+ (high) | 10,492 | 83.6 (82–85.2) |
| 12,097 | 95.2 (93.5–96.9) |
|
|
| NHW men | |||||||
| <5% (low) | 11,350 | 79.5 (78.0–81.0) | Ref | 11,542 | 80.9 (79.4–82.4) | Ref | 1.02 (0.99–1.04) |
| 5.0–9.9% | 12,637 | 79.3 (77.9–80.7) | 1.00 | 12,907 | 80.9 (79.5–82.3) | 1.00 | 1.02 (0.99–1.04) |
| 10.0–19.9% | 12,604 | 80.7 (79.3–82.2) | 1.02 | 13,759 | 87.7 (86.2–89.2) |
|
|
| 20+ (high) | 5,388 | 88.4 (86.0–90.8) |
| 5,924 | 96.5 (94.0–99.0) |
|
|
| NHB men | |||||||
| <5% (low) | 505 | 86.5 (78.4–95.3) | Ref | 576 | 100.7 (91.8–110.2) | Ref | 1.16 (1.02–1.33) |
| 5.0–9.9% | 836 | 80.9 (75–87.2) | 0.94 | 957 | 92.1 (85.9–98.8) | 0.92 | 1.14 (1.03–1.26) |
| 10.0–19.9% | 1,628 | 85.4 (80.9–90) | 0.99 | 1,929 | 99.2 (94.4–104.1) | 0.99 | 1.16 (1.08–1.25) |
| 20+ (high) | 2,700 | 97.8 (94–101.8) |
| 3,265 | 117.8 (113.5–122.1) |
| 1.20 (1.14–1.27) |
| Hispanic men | |||||||
| <5% (low) | 619 | 79.4 (72.8–86.4) | Ref | 657 | 82.6 (75.9–89.7) | Ref | 1.04 (0.92–1.17) |
| 5.0–9.9% | 978 | 69.4 (64.8–74.2) |
| 1,102 | 77.2 (72.5–82.2) | 0.93 | 1.11 (1.01–1.22) |
| 10.0–19.9% | 1,716 | 67.2 (63.8–70.6) |
| 2,098 | 80.9 (77.2–84.6) | 0.98 |
|
| 20+ (high) | 2,034 | 64.4 (61.5–67.4) |
| 2,470 | 76.3 (73.2–79.5) | 0.92 |
|
| API men | |||||||
| <5% (low) | 628 | 63.4 (58.2–68.9) | Ref | 644 | 65.7 (60.4–71.3) | Ref | 1.04 (0.92–1.17) |
| 5.0–9.9% | 518 | 59.7 (54.5–65.4) | 0.94 | 590 | 67.0 (61.5–73.0) | 1.02 | 1.12 (0.99–1.27) |
| 10.0–19.9% | 598 | 63.4 (58.3–68.9) | 1.00 | 711 | 75.2 (69.5–81.1) |
| 1.18 (1.06–1.33) |
| 20+ (high) | 370 | 64.1 (57.7–71.1) | 1.01 | 438 | 75.7 (68.6–83.2) |
| 1.18 (1.02–1.36) |
| All women | |||||||
| <5% (low) | 11,712 | 56.9 (55.8–57.9) | Ref | 13,140 | 63.4 (62.3–64.5) | Ref | 1.12 (1.09–1.14) |
| 5.0–9.9% | 13,681 | 56.4 (55.5–57.4) | 0.99 | 15,226 | 62.2 (61.2–63.2) | 0.98 | 1.10 (1.08–1.13) |
| 10.0–19.9% | 15,301 | 56.2 (55.3–57.1) | 0.99 | 17,915 | 65.4 (64.4–66.4) |
|
|
| 20+ (high) | 9,879 | 58.2 (57.0–59.4) | 1.02 | 11,577 | 67.9 (66.6–69.1) |
|
|
| NHW women | |||||||
| <5% (low) | 10,113 | 57.3 (56.1–58.4) | Ref | 11,294 | 63.6 (62.4–64.8) | Ref | 1.11 |
| 5.0–9.9% | 11,339 | 56.6 (55.6–57.7) | 0.99 | 12,572 | 62.3 (61.2–63.5) | 0.98 | 1.10 (1.07–1.13) |
| 10.0–19.9% | 11,544 | 57.4 (56.3–58.4) | 1.00 | 13,401 | 66.3 (65.2–67.5) |
|
|
| 20+ (high) | 4,994 | 60.8 (59.1–62.6) |
| 5,642 | 69.1 (67.3–71) |
| 1.14 (1.09–1.18) |
| NHB women | |||||||
| <5% (low) | 534 | 66.6 (60.9–72.6) | Ref | 580 | 73.1 (67.1–79.4) | Ref | 1.10 (0.97–1.24) |
| 5.0–9.9% | 941 | 64.3 (60.2–68.7) | 0.97 | 1,041 | 72.1 (67.7–76.7) | 0.99 | 1.12 (1.02–1.23) |
| 10.0–19.9% | 1,748 | 63.3 (60.3–66.4) | 0.95 | 2,145 | 77.4 (74.1–80.8) | 1.06 | 1.22 (1.15–1.30) |
| 20+ (high) | 2,914 | 69.5 (67–72.1) |
| 3,419 | 81.8 (79–84.6) |
| 1.18 (1.12–1.24) |
| Hispanic women | |||||||
| <5% (low) | 534 | 50.6 (46.3–55.2) | Ref | 684 | 65.8 (60.8–71) | Ref | 1.30 (1.16–1.46) |
| 5.0–9.9% | 896 | 48.9 (45.7–52.3) | 0.97 | 1,036 | 56.6 (53.1–60.2) |
| 1.16 (1.06–1.27) |
| 10.0–19.9% | 1,477 | 44.8 (42.6–47.2) |
| 1,760 | 53.4 (50.9–56) |
| 1.19 (1.11–1.28) |
| 20+ (high) | 1,654 | 41.9 (39.9–44) |
| 2,078 | 52.3 (50.1–54.7) |
| 1.25 (1.17–1.33) |
| API women | |||||||
| <5% (low) | 531 | 44.2 (40.5–48.3) | Ref | 582 | 48.2 (44.2–52.3) | Ref | 1.09 (0.96–1.23) |
| 5.0–9.9% | 505 | 43.6 (39.8–47.7) | 0.99 | 577 | 50.5 (46.4–54.9) | 1.05 | 1.16 (1.02–1.31) |
| 10.0–19.9% | 532 | 43.5 (39.8–47.4) | 0.98 | 609 | 49.3 (45.4–53.5) | 1.02 | 1.13 (1.01–1.28) |
| 20+ (high) | 317 | 41.2 (36.8–46) | 0.93 | 438 | 56.7 (51.5–62.3) |
|
|
aData are from selected population-based cancer registries that participate in the National Program of Cancer Registries (NPCR) and/or the Surveillance Epidemiology and End Results (SEER) Program: Arizona, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Iowa, Louisiana, Minnesota, New York, New Jersey, Texas, Utah, West Virginia, and Los Angeles.
bColon and rectum (CRC) included ICD-O-3 codes C18.0–C18.9, C19.9, C20.9, and C26.0.
cEarly (in situ and localized).
dLate (regional and distant).
CRC: colon and rectum cancer; IRR: incidence rate ratio; CI: confidence interval; NHW: non-Hispanic white; NHB: non-Hispanic black; API: Asian Pacific Islander.
∗Statistically significant IRR (P < 0.05); reference (<5% below poverty).
†Statistically significant difference (P < 0.05) in late-to-early stage IRR by poverty level is based on z-statistic. Difference is based on comparison of late-to-early stage IRRs for the two highest poverty categories with the lowest poverty category (<5% below poverty).
Figure 1CRC subsite-specific incidence rate ratios and 95% CIs for late-to-early stage for selected areas in the United States (data are from selected population-based cancer registries that participate in the National Program of Cancer Registries (NPCR) and/or the Surveillance Epidemiology and End Results (SEER) Program: Arizona, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Iowa, Louisiana, Minnesota, New York, New Jersey, Texas, Utah, West Virginia, and Los Angeles). aProximal included ICD-O-3 codes C18.0, C18.2, C18.3, C18.4, and C18.5. bDistal included ICD-O-3 codes 18.6 and C18.7. cRectum included ICD-O-3 codes C19.9 and C20.9. dLate stage includes cases diagnosed at regional or distant stage; early stage includes cases diagnosed at in situ or localized stage. CT, census tract; IRR, incidence rate ratio; CI, confidence interval; N, number of cases; rates are per 100,000 and age-adjusted to the 2000 US standard population. *Statistically significant difference (P < 0.05) in late-to-early stage IRR by poverty level based on z-statistic. Difference is based on comparison of late-to-early stage IRRs for highest poverty categories with the lowest poverty category.